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Objective: Polymerase gamma (POLG) mutations are a common cause of mitochondrial disease and have also been
linked to neurodegeneration and aging. We studied the molecular mechanisms underlying POLG-related neurode-
generation using postmortem tissue from a large number of patients.
Methods: Clinical information was available from all subjects. Formalin-fixed and frozen brain tissue from 15 patients
and 23 controls was studied employing a combination of histopathology, immunohistochemistry, and molecular stud-
ies of microdissected neurons.
Results: The primary consequence of POLG mutation in neurons is mitochondrial DNA depletion. This was already
present in infants with little evidence of neuronal loss or mitochondrial dysfunction. With longer disease duration, we
found an additional, progressive accumulation of mitochondrial DNA deletions and point mutations accompanied by
increasing numbers of complex I–deficient neurons. Progressive neurodegeneration primarily affected the cerebellar
systems and dopaminergic cells of the substantia nigra. Superimposed on this chronic process were acute, focal cort-
ical lesions that correlated with epileptogenic foci and that showed massive neuronal loss.
Interpretation: POLG mutations appear to compromise neuronal respiration via a combination of early and stable
depletion and a progressive somatic mutagenesis of the mitochondrial genome. This leads to 2 distinct but overlap-
ping biological processes: a chronic neurodegeneration reflected clinically by progressive ataxia and cognitive impair-
ment, and an acute focal neuronal necrosis that appears to be related to the presence of epileptic seizures. Our
findings offer an explanation of the acute-on-chronic clinical course of this common mitochondrial encephalopathy.
ANN NEUROL 2014;76:66–81
Polymerase gamma (POLG) replicates and repairsmitochondrial DNA (mtDNA). Mutations in POLG,
the gene encoding the catalytic subunit, are among the
most common causes of mitochondrial disease1 and have
been linked to ageing2 and neurodegeneration.3–6 POLG
mutations cause a variety of clinical phenotypes, includ-
ing devastating encephalopathy syndromes that affect
both adults and children, and that range from infantile
hepatocerebral disease (Alpers–Huttenlocher syndrome)
to juvenile or adult onset disorders with progressive
spinocerebellar ataxia and epilepsy, known as mitochon-
drial recessive ataxic syndrome or mitochondrial spino-
cerebellar ataxia and epilepsy (MSCAE).7–9
The molecular pathogenesis of POLG encephalopathy
is not fully understood, and its study is limited by the lack
of accurate models. Human tissue is of limited availability,
cell culture commonly does not express the molecular
defects seen in tissue, and no animal models exist that
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accurately reflect human POLG encephalopathy syndromes.
It is known that POLG mutations affect the enzyme’s abil-
ity to efficiently replicate and repair mtDNA,10,11 and
patients with POLG disease do harbor mtDNA damage
and signs of respiratory chain dysfunction in affected tis-
sues.12–15 The nature of the mtDNA defect appears to dif-
fer depending on which tissue is studied,1,12,16 with the
central nervous system (CNS) being least well understood
due to the difficulties in obtaining human tissues to study.
The few human studies of neuronal mtDNA in
POLG disease have shown inconsistent results. Multiple
mtDNA deletions affecting between 20 and 50% of
mtDNA molecules have been identified,12–15 but whether
this level of mtDNA deletion alone is sufficient to cause
respiratory dysfunction and neuronal death remains
unclear.17 Both normal and mildly decreased (70–75% of
control) mtDNA copy number have been found in brain
homogenate,12,13,16,18 and 1 study in neurons from the
dorsal root ganglia of a single patient15 has reported clear
mtDNA depletion (50% of controls). Accumulation of
mtDNA point mutations has been shown in skeletal mus-
cle of patients with POLG disease using an ultradeep
resequencing-by-synthesis (UDS) assay,19,20 whereas no
increase in mtDNA point mutations was detected in
another study in brain.12 This study used a strategy of
polymerase chain reaction (PCR) and cloning that has
limited sensitivity, however, and cannot exclude mutations
present at low heteroplasmy levels.
POLG disease affecting the brain often manifests as
an acute-on-chronic process.8,9 To understand this at the
level of the neuron, we investigated the changes in respira-
tory chain proteins and mtDNA in extensive material
comprising tissue from all major areas of the CNS from
15 patients aged 0.6 to years 53 years with encephalopathy
syndromes caused by the most common POLG mutations
(c.1399G>A, p.A467T or c.2243G>C, p.W748S). Our
findings show that it is possible to construct a sequence of
events linking early quantitative loss of mtDNA and sub-
sequent accumulation of mtDNA damage to respiratory
chain deficiency and neuronal injury.
Subjects and Methods
Patients and Controls
Postmortem CNS tissue from 15 patients with POLG encephal-
opathy and 23 controls was studied. Demographic data and the
tissues and studies that were performed are summarized in the
Supplementary Table.
The patients all had a progressive MSCAE with focal and
secondary generalized seizures and suffered at least 1 strokelike
episode with cortical strokelike lesions on magnetic resonance
imaging (MRI). In 12 patients for whom electroencephalographic
(EEG) data were available, the localization of the cortical lesions
correlated with epileptiform activity. Three patients had infantile
onset encephalopathy with severe epilepsy and strokelike episodes.
The clinical and genetic features of all patients are summarized in
Table 1 and have been described elsewhere in detail.8,9
Controls had no known neurological disease or injury,
did not use antiviral medication, and had normal routine his-
tology in all brain samples collected. Fresh frozen tissue was
collected prospectively from 17 controls, comprising 12 adults
and children with a mean age of 42.36 22.2 years and 5
infants (<1 year old) with a mean age of 0.116 0.16 years;
formalin-fixed paraffin-embedded (FFPE) tissue was available
from a further 6 subjects with an average age of 426 9.7 years
and an 85-year-old patient with advanced, histologically con-
firmed Alzheimer disease.
Tissue Material
Samples were collected from the frontal, temporal, and occipital
cortex, hippocampus, thalamus, striatum (putamen), cerebellar
cortex, dentate nucleus, mesencephalon at the level of the sub-
stantia nigra, pons, medulla oblongata at the level of the inferior
olivary nucleus, and cervical spinal cord. Samples were dissected
at autopsy and either snap-frozen in isopentane cooled in liquid
nitrogen and stored at 280C or fixed in formaldehyde and
embedded in paraffin blocks according to standard procedures.
There were no significant differences in postmortem interval or
length of fixation between patient and control tissue.
Histology and Morphometric Analysis
Routine investigation of FFPE sections included hematoxylin and
eosin (H&E), cresyl violet, Luxol myelin stain, and glial fibrillary
acidic protein immunohistochemistry. Routine morphological
examination with H&E was performed on all samples from all
patients and controls. Morphometric analysis and cell counting
were performed using a light microscope (Leica, Wetzlar, Ger-
many) equipped with a Zeiss AxioCam MRc5 camera and Zen
2011 software (Carl Zeiss MicroImaging, Jena, Germany). Cell
counting was performed on 4lm-thick sections immunohisto-
chemically stained for porin (which stains all neurons irrespective
of respiratory chain status) in the cerebellar cortex, dentate
nucleus, and inferior olivary nucleus. Only neurons with a clearly
visible nuclear morphology were counted. In the cerebellum, the
length of the Purkinje cell layer was measured at 325 magnifica-
tion, all Purkinje cells fulfilling the above criteria were counted,
and cell density was calculated as Purkinje cells/mm. The total
area of the dentate and inferior olivary nuclei available on the sec-
tion was measured, neurons were counted as above, and neuronal
density was calculated as neurons/mm2. Eosinophilic neuronal
necrosis was defined as neurons with intensely eosinophilic cyto-
plasm and pyknotic nucleus with no discernible nucleolus.
Histochemistry and Immunohistochemistry
Immunohistochemistry for respiratory complexes I, II, III, and
IV and the mitochondrial membrane protein porin was per-
formed on 15 patients and histochemistry for cytochrome oxi-
dase (COX) and succinate dehydrogenase (SDH) on 8 as
previously described.6
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Cell Death Studies
Ten patients and 7 controls were studied (see Supplementary
Table) by caspase-3 immunohistochemistry and terminal deoxy-
nucleotide transferase–mediated deoxyuridine triphosphate nick-
end labeling (TUNEL) assay. Caspase-3 immunohistochemistry
was performed as previously described.6 TUNEL was performed
on 8lm-thick frozen sections using a commercial kit (In Situ
Cell Death Detection Kit, Fluorescein, v16.0; Roche, Basel,
Switzerland) according to the manufacturer’s protocol.
Neuron Microdissection
Neurons for mtDNA analysis were microdissected from differ-
ent CNS areas of 8 patients and 17 age-matched controls (see
Supplementary Table). Microdissection and cell lysis were car-
ried out as previously described.6 Only cells that could be posi-
tively identified as neurons, with a visible nucleus and normal
morphological characteristics, were used. For each area, there
was no significant size difference between neurons of patients
and corresponding controls. A total of 4,012 neurons were
picked from 8 patients (n5 1,896) and 17 age-matched con-
trols (n5 2,116). Neurons were microdissected, avoiding carry-
over of glia or other cells, and pooled in groups of 10 in the
cortex (n5 2,456 pyramidal neurons in total) and hippocampal
CA formation (n5 250); 15 in the substantia nigra (n5 360);
5 in the cerebellum (n5 490 Purkinje cells), dentate (n5 165
principal dentate neurons), and olivary (n5 175 principal oli-
vary neurons) nuclei; and 4 in the anterior horn of the spinal
cord (n5 116 alpha motor neurons).
mtDNA Studies
mtDNA quantification and deletion assessment was performed
in gray matter homogenate and in microdissected neurons of 8
patients and 17 age-matched controls (see Supplementary
Table) using quantitative PCR (qPCR) and long-range PCR
(LPCR) as previously described.6 Assessment of mtDNA point
sequence variants was performed in genomic DNA extracted
from frontal cortical homogenate of 6 patients (2 A467T
homozygous and 4 W748S homozygous) and 5 age-matched
controls (see Supplementary Table). Point mutations were
detected with an UDS assay using FLX GS technology (Roche
454 Life Sciences, Branford, CT) as previously described.20
Two regions of mtDNA were amplified and subsequently
sequenced: 1 in the noncoding hypervariable region MT-HV2,
known to have a high mutational rate, and 1 in the highly con-
served, peptide-coding MT-CO3 gene. PCR products were puri-
fied using Agencourt Ampure XP beads (Beckman Coulter,
Fullerton, CA) and quantified using a Qubit 2.0 Fluorometer
(Life Technologies, Grand Island, NY). Samples were pooled
into equimolar libraries and processed for bidirectional ampli-
con sequencing using Titanium (XLR70) chemistry (Roche)
and a GS-FLX (v2.8 sequencing software) according to the
manufacturer’s instructions (Roche).
Bioinformatic Analyses
PyroBayes (v1.1) and Mosaik (v0.9.0891) algorithms were used
in sequence base calling and alignment. Subsequent analysis of
variants was done within R using a custom-made R library
flowgram.19 Homopolymer tracts (n 4) within the amplicons
were excluded from analysis, to minimize pyrosequencing
derived base-calling error. Variants were recorded if present in
both directions with 0.2% heteroplasmy as previously
described.20
Statistical Analyses
Statistical analyses were performed in SPSS (v.20.0.0.1; IBM,
Armonk, NY) and Prism (v6; GraphPad, San Diego, CA).
Comparison of proportions of point mutations between groups
was done by chi-square test. Comparison of mtDNA quantity
between groups was performed by Mann–Whitney U test. Cell
densities were compared by 2-tailed t test, and correlation anal-
ysis was done using Pearson coefficient.
Results
POLG Mutations Cause Acute Focal Neuronal
Necrosis Superimposed on a Background of
Chronic Neurodegeneration
Histopathological findings fell into 3 categories: acute
focal lesions, diffuse progressive changes with uniform
intraregional distribution, and mildly or unaffected areas.
These findings are detailed in Table 2.
Focal, sharply demarcated lesions were seen in the
neocortex (14 of 14 patients), hippocampus CA region
(4 of 14), thalamus (2 of 9), and cerebellar cortex (9 of
14). These were characterized by selective neuronal loss,
eosinophilic neuronal necrosis, vacuolation of the neuro-
pil, astrocytosis, and diffuse microglial activation (Fig 1,
Table 2). Neuronal loss in the cerebral cortex had a lami-
nar pattern, being most pronounced in the superficial
(II–III) and deep (V–VI) layers. Surviving neurons with
normal cytoplasmic and nuclear morphology were scat-
tered throughout the lesion (see Fig 1E, F), and there
was no infiltration by peripheral inflammatory cells. The
cortical microvasculature in and around the lesions was
patent, and in 4 cases increased vascularity was found
within the lesions.
Cortical acute lesions correlated with the localiza-
tion of acute strokelike lesions on MRI and epileptiform
activity on EEG, and there was a clear predilection for
the occipital and frontal lobes, whereas the temporal neo-
cortex was universally spared (histologically and on
MRI). All 4 patients with the earliest disease onset and
age of death had focal lesions confined to the CA1 area
of the hippocampus, whereas the hippocampal formation
showed normal morphology in the remaining patients.
Focal lesions were seen in the cerebellar cortex of 8
patients and were characterized by severe Purkinje and
granule cell loss and Bergmann gliosis. These lesions
could be multiple, but were often microscopic (Fig 2E,
F) and not always detected by MRI.
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FIGURE 1: Histopathological and immunohistochemical analysis of acute lesions in polymerase gamma encephalopathy. Brain
histology from a representative patient (WS-1A) compares unaffected cortex (left side, A–D) and an acute cortical lesion (right
side, E–I). Sections are either stained with hematoxylin and eosin (A, E, F), or react immunohistochemically to glial fibrillary
acidic protein (B, G), the microglial marker HLA-DR (C, H), or complex I subunit NDUFB8 (D, I). Original magnification53100.
(F) Magnified (original magnification53400) detail from E. The acute lesion is characterized by severe but incomplete neuro-
nal loss (E and F) and vacuolation of the neuropil. Surviving neurons with normal morphological characteristics (arrows in F) are
scattered throughout the acute lesion. There is pronounced astrocytosis (G) and diffuse microglial activation (H). In the neigh-
boring, morphologically preserved cortex (D, arrows), there is a high proportion of complex I–negative neurons, but only com-
plex I–positive cells survive within the acute lesion (I). Scale bars5100lm (A–C, E, G, H), 50lm (D, F, I).
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Diffuse, uniformly distributed changes consisted of
neuronal loss and gliosis affecting mainly the cerebellar
dentato-olivary and dentatorubral systems, thalamus, and
substantia nigra. In the cerebellar cortex, there was diffuse,
uniform Purkinje cell loss in addition to the focal lesions
(see Fig 2). The dentate nucleus showed severe neuronal
loss in addition to pronounced cytoplasmic accumulation
of lipofuscin pigment in remaining neurons. Purkinje cell
loss was significantly (p5 0.0006) more severe in patients
homozygous for W748S and compound heterozygous
patients (Purkinje cell count5 29.26 14.1% of controls)
than in the A467T homozygous patients, who showed
only mild reduction of Purkinje cell numbers (Purkinje
cell count5 81.56 13.4% of controls). Neuronal loss in
the dentate also appeared to be more pronounced in the
W748S and compound heterozygous patients (dentate
neuronal count5 47.76 28.5% of controls) than in the
A467T homozygous patients (dentate neuronal
count5 82.46 22.6% of controls), but this difference
was not statistically significant. Cerebellar neuronal loss
correlated with MRI findings of more pronounced cere-
bellar and dentate atrophy in the W748S homozygous
and compound heterozygous patients than in the A467T
homozygous patients. Despite this, we detected no signifi-
cant clinical difference in the severity of ataxia in the 2
groups.
FIGURE 2: Cerebellar pathology in polymerase gamma encephalopathy: comparison of patients with the W748S and/or A467T
mutations. Cerebellar sections from patients stained with hematoxylin and eosin (A–D) or porin immunohistochemistry (E, F)
are shown. Patients are homozygous for the A467T (A, B), homozygous for the W748S (C, D), or compound heterozygous in
transit for the A467T and W748S mutations (E, F). The cerebellum shows a combination of 2 types of pathology: diffuse neuro-
degeneration with Purkinje cell loss, Bergmann gliosis, and thinning of the molecular layer (A–F) and microscopic focal, sharply
demarcated lesions (E, F). Diffuse degenerative changes are significantly more severe in the W748S homozygous (C, D) and
compound heterozygous (E, F) compared to A467T homozygous (A, B) patients.
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The thalamus was abnormal in all patients studied
(9 of 9), showing diffuse neuronal loss and gliosis in
addition to circumscribed focal lesions in 2 patients. In
the substantia nigra, there was severe loss of pigmented,
dopaminergic neurons, which was most pronounced in
the ventrolateral tier. A detailed description of the nigral
pathology is described elsewhere.6 In the brainstem, there
was pronounced neuronal loss and gliosis in the locus
coeruleus6 and the inferior olivary nucleus. In the spinal
cord, there was severe, selective degeneration of the dor-
sal funiculus, which was more pronounced in the fascicu-
lus gracilis, as previously described.9
Regions of the cerebral neocortex and hippocampus
not affected by focal lesions and the striatum showed
either normal morphology or only mild neuronal loss as
evidenced by mildly increased numbers of astrocytes in
the cortex and underlying white matter. The pons and
medulla oblongata appeared structurally preserved, with
the exception of the locus coeruleus and olivary nucleus.
Patient Neurons Show Selective and
Progressively Increasing Deficiency of
Respiratory Complex I
Immunohistochemistry revealed significant numbers of
complex I–deficient neurons in POLG patients (Table 3,
Fig 3), but no deficiency of complexes II and III or porin
and only a small number of complex IV–deficient neu-
rons identified either by COX/SDH histochemistry or
immunohistochemistry. No respiratory chain–deficient
neurons were found in the controls, with the exception
of a few complex I–negative neurons in the substantia
nigra (12.5%) and the CA area of the hippocampus
(<1%) of the patient with Alzheimer disease.
The numbers of neurons negative for complex I
and IV varied according to region and which type of
pathological process affected the area under scrutiny. In
focal, acute lesions, with few remaining neurons, most
surviving neurons retained complex I staining (see Fig
1I). Thus, the proportion of complex I–negative neurons
was significantly lower in these areas (p5 0.03) than in
those affected by the chronic process. Acute lesions also
contained no complex IV–negative cells. In regions with
better-preserved neuronal populations, that is, chronically
affected, there were abundant complex I–deficient neu-
rons, and the relative proportion of deficient to nondefi-
cient neurons was accordingly higher (see Table 3, Figs
1D and 3A). Moreover, in these regions with surviving
neurons, the number of neurons deficient for complex I
(and IV) increased significantly with patient age (see Fig
3J). Few complex I–negative neurons were found in the
infant patients, with the exception of the substantia
nigra, which showed 60% complex I–negative neurons
already at the age of 1 year (Patient AL-2A).
The most severe complex I (and IV) defects were
found in the substantia nigra, red nucleus, olivary
nucleus, and central basal pontine nuclei (peduncular
and median), followed by the dentate nucleus, cerebellar
Purkinje cells, hippocampal CA2 and CA4 areas, and
cerebral neocortex (see Table 3). There was no significant
difference in the numbers of neurons negative for com-
plex I or IV between the frontal, temporal, and occipital
cortices. The mean ratio of complex IV–negative to com-
plex I–negative neurons showed regional variation being
substantially higher in the cerebral cortex (0.35) and Pur-
kinje cells (0.23) than in deeper nuclei, including the
dentate (0.03), inferior olive (0.008), and substantia
nigra (0.02).
Studies of Cell Death
Caspase-3 staining revealed no positive nuclei in any of
the patients. TUNEL was negative in the adult patients,
whereas several positive nuclei were seen in Patients AL-
1A (age51 year) and AL-1B (age5 8 years). The
same areas were, however, negative for caspase-3.
POLG Mutations Cause Early Quantitative
Depletion and Progressive Accumulation of
Somatic Damage in the Mitochondrial Genome
Quantification of mtDNA in gray matter homogenate
showed normal (n5 5) or moderately reduced (n5 2)
mtDNA levels in adult patients and apparent depletion
(20–30% of age-matched controls) in the children
(Patients AL-1A and AL-1B). Investigation of microdis-
sected neurons, however, revealed a different picture.
Patient neurons consistently showed a substantial
mtDNA depletion compared with age-matched control
microdissected neurons; patients had approximately
406 11% (range5 17–56%) of control mtDNA. This
difference was found throughout the CNS, with no
regional differences, and was highly significant (Figs 4
and 5C). Infants (1 year old) had a significantly lower
neuronal mtDNA copy number than older individuals,
in both the patients and controls. Neuronal mtDNA lev-
els of postinfant and adult patients did not exceed those
of control infants (see Fig 4).
Deletions of mtDNA were detectable by LPCR in
gray matter homogenate and single neurons of patients.
Deletions appeared as smears on homogenate PCR,
whereas single neurons contained 1 deleted species (see
Fig 5). Relative quantification of deleted mtDNA by
qPCR in microdissected neurons showed that deletion
levels in the patients ranged from undetectable in most
CNS areas of the infant (Patient AL-1A) and child
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FIGURE 3: Respiratory chain dysfunction in polymerase gamma (POLG) encephalopathy. Serial sections of the hippocampal
CA2 region (A–F) and inferior olivary nucleus (G–I) from a representative patient (AT-1B) are shown. There is severe and selec-
tive complex I (anti-NDUFB8) deficiency (A, G), with only a few complex IV–negative neurons in the hippocampus (D) and none
in the olive (H), and normal staining for complexes II (B), III (C), and porin (E, I). Complex I stained all neurons in control hippo-
campus (F). Neuronal complex I deficiency is progressive in POLG encephalopathy (J). The proportion of complex I–negative
neurons increased with age in all central nervous system areas studied. The diagrams in J show the percentage of complex I–
negative neurons (y-axis) as a function of individual patient age in years (x-axis) in the frontal cortex, hippocampal CA2 region,
substantia nigra, and anterior spinal horn. The dopaminergic neurons of the substantia nigra are the earliest among the studied
areas to manifest complex I loss.
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(Patient AL-1B) to 40% higher than age-matched con-
trols in the older adults with the longest disease duration.
Notably, the highest levels of excess mtDNA deletion
compared to controls were found in the dopaminergic
neurons of the substantia nigra. The proportion of
deleted mtDNA in the patients significantly increased
with age, accumulating at substantially higher levels than
in controls.
FIGURE 4: mtDNA relative quantification in microdissected neurons from patients with polymerase gamma encephalopathy.
Each point is a pooled sample of 5 to 15 neurons. For the purposes of comparison, a control sample has been arbitrarily set to
1. Groups are compared by Mann–Whitney U test, and p values are shown above each graph; n5number of individuals in
each group. Patient neurons from all central nervous system areas examined contain significantly less (50–60%) mtDNA than
neurons of age-matched controls. The top left panel shows in addition that infants (£1 year old) have lower neuronal mtDNA
content compared to older individuals, in both the patients (infant 26% of postinfant values) and controls (infants 38% of post-
infant values).
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The UDS assay of mtDNA had a mean coverage of
>8,500 sequence reads per amplicon in both forward
and reverse directions. The overall burden of mtDNA
point mutations present at a frequency >0.2% was sig-
nificantly higher in patients compared to age-matched
controls in both MT-HV2 (odds ratio [OR]5 3,
p< 0.0001) and MT-CO3 (p5 0.025). No sequence var-
iation detectable at a frequency >0.2% was found in the
highly conserved MT-CO3 region of the controls. MT-
HV2 had a significantly higher mutational load than
MT-CO3 in both patients and controls (p> 0.0001 for
both groups). The great majority of excess point muta-
tions in the patients were present at low heteroplasmy
levels (<2%), and their frequency decreased dramatically
with increasing heteroplasmy. Overall mutational burden
in MT-HV2 was significantly higher in A467T than
W748S homozygous patients (OR5 1.86, p5 0.008; Fig
6A), but A467T homozygous patients were also older,
and this difference was no longer significant when cor-
rected for age. In the patients, the burden of point muta-
tions showed an apparent increase with age, although
this did not reach statistical significance due to the small
sample size (r5 0.74, p5 0.09). No age-dependent
increase of point variants was seen in the controls
(r5 0.27, p5 0.67; see Fig 6B).
Discussion
Using a combination of clinical, neuropathological, and
molecular investigations, we have defined the evolution
of this devastating mitochondrial encephalopathy. The
earliest feature appears to be depletion of neuronal
mtDNA; this was present in the very youngest
FIGURE 5: Neuronal mtDNA deletions in polymerase gamma encephalopathy. Long polymerase chain reaction analysis of
mtDNA deletions in cortical homogenate (A) and single microdissected neurons (B) from the frontal cortex of patients and con-
trols is shown. (A) Amplification of an 11kb mtDNA fragment in DNA from cortical homogenate. Samples from left to right: 2
controls and 4 patients aged 8, 44, 41, and 24 years, respectively. No deletions are seen in the child, whereas older patients
show smears consistent with multiple deletions, which are more pronounced in the older individuals. (B) Results from single
microdissected neurons. A nested amplification of an 8kb product was performed from an 11kb amplicon in patients and con-
trols. All patient neurons contain 1 deleted species. Deletions are also detected in some of the control neurons, but quantifi-
cation shows these to be at substantially lower levels than in patients (C, D). Arrows in A and B mark the normal band size.
The ladders are 1kb (Gene Ruler). (C) The relative proportions of mtDNA depletion and deletion in microdissected neurons
from various areas of the nervous system. Each bar represents the mean with standard deviations; blue bars show mean
patient neuronal mtDNA copy number relative to controls, and red bars show levels of nondeleted neuronal mtDNA relative
to controls. Depletion levels are similar throughout the nervous system, whereas excess deletion (compared to age-matched
controls) is most pronounced in the substantia nigra. (D) The proportion of deleted mtDNA in patient neurons in excess of that
seen in age-matched controls is plotted against patient age in years. The level of excess mtDNA deletions increases with
patient age in frontal (r50.81), occipital (r50.78), and Purkinje (r50.97) neurons. A similar progressive increase in deletions
was found in all brain areas examined.
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individuals, who showed little or no morphological
abnormality. Gradual loss of complex I in neurons and
increasing levels of multiple mtDNA deletions and point
mutations correlated with the chronic loss of neurons.
Clinically, acute episodes correlated with strokelike
lesions on MRI and an epileptic focus on EEG, and
these in turn could be correlated with the acute focal
pathological lesions that were identified throughout the
cortex and in deeper structures. The correlations of clini-
cal, pathological, and molecular features in POLG ence-
phalopathy are summarized in Table 4.
Mutations in POLG cause a combination of
mtDNA damage in the CNS including quantitative
depletion, multiple deletions, and an increased burden of
point mutations. Our data show that the detection and
accurate quantification of depletion require studies in
microdissected neurons. Quantitative studies in brain
homogenate either underestimate mtDNA depletion, due
to the presence of non-neuronal cells with normal
mtDNA levels, or overestimate it, as in cases with severe
global destruction, such as Patients AL-1B and AL-1A.
Furthermore, we show that mtDNA depletion is both a
universal phenomenon, that is, found in all patient neu-
rons irrespective of type or site, and an early, but non-
progressive event starting before the first year of life.
That depletion remains unchanged irrespective of how
long the patients lived with the disease raises the possibil-
ity that there is an absolute level below which it is not
possible for the cell to survive.
Whether mtDNA depletion is present already in
the ovum and/or reflects incomplete mtDNA copy
number expansion during embryogenesis is unknown.
Neuronal mtDNA content is known to increase from
infant to adult life in normal individuals, most probably
as a result of neuronal differentiation and growth. That
the lowest mtDNA levels were found in the affected
infant suggests that a developmental defect of mtDNA
synthesis is present in patients with POLG mutations
compromising this initial expansion of mtDNA. Dele-
tions of mtDNA could not be detected in the youngest
patients, but appeared in neurons of patients with longer
disease duration (and who were older) at levels substan-
tially higher than controls. Deletions affected all CNS
areas studied, but showed a predilection for neurons of
the substantia nigra. Nigral neurons have a known inher-
ent predisposition for accumulating mtDNA deletions
both with age and in conditions associated with neurode-
generation.21–23 One study suggested this may be related
to the dopaminergic metabolism24; however, irrespective
of etiology, the predilection of nigral neurons for
mtDNA deletions correlates with the early and severe
complex I deficiency and neuronal loss in this area, sug-
gesting that they play an important pathogenic role.6
We show that UDS is an effective method and
superior to cloning-based techniques for detecting and
measuring somatic mtDNA mutagenesis in the brain.
The finding of increased levels of mtDNA point muta-
tions in the brain of patients with POLG mutations is
novel. Although similar to previous findings in skeletal
muscle,19,20 the mutational burden appeared higher in
the brain, correlating with its more severe involvement in
this type of POLG disease. The low individual frequency
FIGURE 6: Results of ultradeep resequencing-by-synthesis (UDS) in the brain of patients with polymerase gamma (POLG) ence-
phalopathy. (A) Comparison of mtDNA point mutation burden (at >0.2% frequency) in the MT-HV2 region, in the brain of
POLG encephalopathy patients and controls. Patients have a significantly higher burden of low-frequency mutations compared
to age-matched controls (odds ratio [OR]53, p<0.001). Patients homozygous for the A467T (AT) mutation have significantly
more point mutations than patients homozygous for the W748S (WT) (OR51.86, p50.008). (B) The number of point mutations
(x-axis) detected by UDS in the brain of individual patients is plotted against patient age in years (y-axis). A clear trend
(r50.74, p50.09) for progressive age-dependent increase of mutations is seen in the patients, but not in the controls.
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of each mutation explains why they were not detected by
less sensitive techniques.12 Our data suggest a progressive
age-dependent accumulation of point mutations in the
patients, and the finding that most occur at very low
individual frequencies (<1%) suggests that these are
acquired somatic mutations caused by increased error
rate and/or impaired repair function of POLG. More-
over, the preexisting mtDNA depletion may be enhanc-
ing the process of mutagenesis by limiting the available
pool of mtDNA molecules and facilitating the clonal
expansion of those somatic mutations within cells.
Although these mutations occurred at very low fre-
quencies, a pathogenic contribution cannot be excluded.
If point mutations occur exclusively or primarily in neu-
rons, quantifying them in brain homogenate will under-
estimate their proportion in neuronal cells. Moreover, by
occurring on a background of already substantial
mtDNA damage due to depletion and accumulating
deletions, point mutations decrease further the number
of wild-type mtDNA molecules available for respiratory
complex synthesis, bringing the cells closer to the thresh-
old for respiratory deficiency.
In the face of a substantially decreased mtDNA
copy number and progressive decline in mtDNA quality,
the development of respiratory chain dysfunction is
hardly surprising. Why this selectively affects complex I
is, however, unclear. One explanation is that complex I
contains the highest number (7) of mtDNA-encoded
subunits, most of which (5) are located within the region
commonly affected by deletion. Moreover, studies suggest
that neuronal complex I is functioning close to its maxi-
mum capacity.25 It may, therefore, be the most vulnera-
ble to defects of mtDNA homeostasis, including
mutations of POLG and Twinkle, the mitochondrial
helicase.26 It has been suggested that the loss of complex
I may be a protective mechanism that serves to limit the
potential damage that an inefficient respiratory chain
might cause.26 Whether complex I deficiency is a pri-
mary consequence of the disease or a secondary adaption
is a question that remains to be addressed. We found no
evidence of increased complex II activity or complex IV
loss, despite the significant degree of mtDNA damage.
Irrespective of what causes the complex I deficiency,
it appears that the ability of neurons to produce energy
is compromised. Our data suggest that this energy defi-
ciency results in 2 distinct but overlapping pathophysio-
logical processes, 1 chronic and 1 acute.
Vulnerable neuronal populations, including those in
the cerebellum, thalamus, and substantia nigra, exhibit a
substantial, time-dependent cell loss. Degeneration of the
cerebellum and its connections, including the dentato-
olivary and dentatorubral systems and dorsal column tracts,
causes a progressive spinocerebellar ataxia. Interestingly,
although cerebellar changes were significantly less pro-
nounced in the A467T homozygous patients, their ataxia
was equally severe. This may have to do with the large
proportion of complex I–negative neurons in their cerebel-
lum and basal pontine nuclei, which relay the cortical
input to the cerebellum. Although these neurons have oth-
erwise normal morphology, it is possible that lack of com-
plex I decreases their metabolic capacity, leading to
functional impairment. Another factor explaining the ataxia
of the A467T patients is the degeneration of the proprio-
ceptive dorsal spinal tracts, which is equally pronounced in
both A467T and W748S homozygous patients.
The cerebral cortex, striatum, and pons appear
more resistant to the chronic effects of complex I defi-
ciency. Neurons in these areas are able to survive, but
can still be seen as primed for injury due to their mar-
ginal energy-generating capacity. Seizures abruptly
increase neuronal energy demand, and we suggest that it
is this that precipitates the acute focal lesions in areas
such as the neocortex, hippocampus, and thalamus. Epi-
leptic activity can also explain the acute lesions in the
cerebellum. Studies have shown that epileptogenic foci
may exist within the cerebellum,27,28 but these are diffi-
cult to detect by surface recordings. Moreover, although
the role of the cerebellum in epileptogenesis remains con-
troversial, studies suggest that it may be secondarily
affected by epileptic activity elsewhere in the cortex.
Studies of perfusion using single photon emission com-
puted tomography and functional MRI show evidence of
increased cerebellar activity during clinical seizures of
cortical source and interictally.29,30 This suggests that
clinical or subclinical cortical epileptic activity may lead
to increased metabolic activity in the cerebellum, trigger-
ing acute focal lesions locally.
Neuronal energy failure would also explain why
apoptosis is not seen; apoptosis requires energy, whereas
necrosis is favored in states of severe energy deficiency.31
We suggest, therefore, that describing these lesions as
“strokelike” is inaccurate, and propose the novel descrip-
tive term focal energy-dependent neuronal necrosis.
In conclusion, this work elucidates the mechanisms
underlying neurodegeneration and clinical evolution in a
mitochondrial encephalopathy. We show how mitochon-
drial dysfunction resulting from accumulating mtDNA
damage leads to chronic neuronal loss in susceptible
regions, while at the same time it primes the brain for
acute injury triggered and propagated by epileptic seiz-
ures. These findings explain the high morbidity and mor-
tality that have been associated with epilepsy in this
disorder and highlight the importance of early detection
and aggressive treatment of seizures in these patients.
ANNALS of Neurology
80 Volume 76, No. 1
Ethical Considerations
Informed consent for the autopsy was obtained from the
families of patients and controls. The tissue study was
approved by the Regional Ethical Committee of Western
Norway (No. 2010/23).
Acknowledgment
This work was supported by grants from the Western
Norway Health Trust, University of Bergen, and Meltzer
Foundation.
We thank the patients and their families for making
this study possible, and Dr A. Molven and E. Fick for
their valuable assistance preparing the tissue material.
Potential Conflicts of Interest
Nothing to report.
References
1. Van Goethem G, Dermaut B, Lofgren A, et al. Mutation of POLG
is associated with progressive external ophthalmoplegia character-
ized by mtDNA deletions. Nat Genet 2001;28:211–212.
2. Trifunovic A, Wredenberg A, Falkenberg M, et al. Premature age-
ing in mice expressing defective mitochondrial DNA polymerase.
Nature 2004;429:417–423.
3. Luoma P, Melberg A, Rinne JO, et al. Parkinsonism, premature
menopause, and mitochondrial DNA polymerase gamma mutations:
clinical and molecular genetic study. Lancet 2004;364:875–882.
4. Luoma PT, Eerola J, Ahola S, et al. Mitochondrial DNA polymer-
ase gamma variants in idiopathic sporadic Parkinson disease. Neu-
rology 2007;69:1152–1159.
5. Balafkan N, Tzoulis C, Muller B, et al. Number of CAG repeats in
POLG1 and its association with Parkinson disease in the Norwe-
gian population. Mitochondrion 2012;12:640–643.
6. Tzoulis C, Tran GT, Schwarzlmuller T, et al. Severe nigrostriatal
degeneration without clinical parkinsonism in patients with poly-
merase gamma mutations. Brain 2013;136(pt 8):2393–2404.
7. Hakonen AH, Heiskanen S, Juvonen V, et al. Mitochondrial DNA
polymerase W748S mutation: a common cause of autosomal
recessive ataxia with ancient European origin. Am J Hum Genet
2005;77:430–441.
8. Tzoulis C, Engelsen BA, Telstad W, et al. The spectrum of clinical
disease caused by the A467T and W748S POLG mutations: a
study of 26 cases. Brain 2006;129(pt 7):1685–1692.
9. Tzoulis C, Neckelmann G, Mork SJ, et al. Localized cerebral
energy failure in DNA polymerase gamma-associated encephalop-
athy syndromes. Brain 2010;133(pt 5):1428–1437.
10. Chan SS, Longley MJ, Copeland WC. The common A467T muta-
tion in the human mitochondrial DNA polymerase (POLG) com-
promises catalytic efficiency and interaction with the accessory
subunit. J Biol Chem 2005;280:31341–31346.
11. Chan SS, Longley MJ, Copeland WC. Modulation of the W748S
mutation in DNA polymerase gamma by the E1143G polymorphism
in mitochondrial disorders. Hum Mol Genet 2006;15:3473–3483.
12. Hakonen AH, Goffart S, Marjavaara S, et al. Infantile-onset spino-
cerebellar ataxia and mitochondrial recessive ataxia syndrome are
associated with neuronal complex I defect and mtDNA depletion.
Hum Mol Genet 2008;17:3822–3835.
13. Zsurka G, Baron M, Stewart JD, et al. Clonally expanded mitochon-
drial DNA mutations in epileptic individuals with mutated DNA
polymerase gamma. J Neuropathol Exp Neurol 2008;67:857–866.
14. Lax NZ, Hepplewhite PD, Reeve AK, et al. Cerebellar ataxia in
patients with mitochondrial DNA disease: a molecular clinicopa-
thological study. J Neuropathol Exp Neurol 2012;71:148–161.
15. Lax NZ, Whittaker RG, Hepplewhite PD, et al. Sensory neuronop-
athy in patients harbouring recessive polymerase gamma muta-
tions. Brain 2012;135:62–71.
16. Ferrari G, Lamantea E, Donati A, et al. Infantile hepatocerebral
syndromes associated with mutations in the mitochondrial DNA
polymerase-gammaA. Brain 2005;128(pt 4):723–731.
17. Suomalainen A, Majander A, Haltia M, et al. Multiple deletions of
mitochondrial-DNA in several tissues of a patient with severe
retarded depression and familial progressive external ophthalmo-
plegia. J Clin Invest 1992;90:61–66.
18. Uusimaa J, Hinttala R, Rantala H, et al. Homozygous W748S muta-
tion in the POLG1 gene in patients with juvenile-onset Alpers syn-
drome and status epilepticus. Epilepsia 2008;49:1038–1045.
19. Payne BA, Wilson IJ, Hateley CA, et al. Mitochondrial aging is
accelerated by anti-retroviral therapy through the clonal expansion
of mtDNA mutations. Nat Genet 2011;43:806–810.
20. Payne BA, Wilson IJ, Yu-Wai-Man P, et al. Universal heteroplasmy
of human mitochondrial DNA. Hum Mol Genet 2013;22:384–390.
21. Kraytsberg Y, Kudryavtseva E, McKee AC, et al. Mitochondrial DNA
deletions are abundant and cause functional impairment in aged
human substantia nigra neurons. Nat Genet 2006;38:518–520.
22. Bender A, Krishnan KJ, Morris CM, et al. High levels of mitochon-
drial DNA deletions in substantia nigra neurons in aging and Par-
kinson disease. Nat Genet 2006;38:515–517.
23. Reeve AK, Krishnan KJ, Elson JL, et al. Nature of mitochondrial
DNA deletions in substantia nigra neurons. Am J Hum Genet
2008;82:228–235.
24. Elstner M, Muller SK, Leidolt L, et al. Neuromelanin, neurotrans-
mitter status and brainstem location determine the differential vul-
nerability of catecholaminergic neurons to mitochondrial DNA
deletions. Mol Brain 2011;4:43.
25. Kann O, Huchzermeyer C, Kovacs R, et al. Gamma oscillations in
the hippocampus require high complex I gene expression and
strong functional performance of mitochondria. Brain 2011;134(pt
2):345–358.
26. Palin EJ, Paetau A, Suomalainen A. Mesencephalic complex I defi-
ciency does not correlate with parkinsonism in mitochondrial DNA
maintenance disorders. Brain 2013;136(pt 8):2379–2392.
27. Lascano AM, Lemkaddem A, Granziera C, et al. Tracking the
source of cerebellar epilepsy: hemifacial seizures associated with
cerebellar cortical dysplasia. Epilepsy Res 2013;105:245–249.
28. Rodin E. Paper recordings of ultrafast frequencies in experimental
epilepsy. Clin EEG Neurosci 2005;36:263–270.
29. Wiest R, Estermann L, Scheidegger O, et al. Widespread grey
matter changes and hemodynamic correlates to interictal epilepti-
form discharges in pharmacoresistant mesial temporal epilepsy. J
Neurol 2013;260:1601–1610.
30. Sequeira KM, Tabesh A, Sainju RK, et al. Perfusion network shift
during seizures in medial temporal lobe epilepsy. PLoS One 2013;
8:e53204.
31. Greijer AE, van der Wall E. The role of hypoxia inducible factor 1
(HIF-1) in hypoxia induced apoptosis. J Clinical Pathol 2004;57:
1009–1014.
Tzoulis et al: POLG-Related Neurodegeneration
July 2014 81
